Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025741 | 0.88 | PRMT5 (0.41) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL1519972 | 0.84 | PRMT5 (0.42) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL30379604 | 0.84 | PRMT5 (0.42) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL12502513 | 0.84 | JAK2 (0.46) | PRMT5WDR77LPLLIPGGSK3A | |
| SCHEMBL15799090 | 0.82 | LPL (0.44) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL5475399 | 0.80 | PRMT5 (0.47) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL16025753 | 0.79 | LRRK2 (0.41) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL17205845 | 0.79 | PRMT5 (0.39) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL17588945 | 0.79 | PRMT5 (0.42) | PRMT5WDR77EGFRLPLLIPG | |
| SCHEMBL31725403 | 0.78 | PRKAG1 (0.48) | PRMT5WDR77LPLLIPGGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-2928893-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312715-B2 | Fused ring derivative as A2A receptor inhibitor | ADORA2A, ADORA2B, ADORA1 | PRMT5 1810/4885WDR77 2671/4885EGFR 1984/4885 |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA2B, ADORA1 | PRMT5 1810/4885WDR77 2671/4885EGFR 1984/4885 |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | PRMT5 1045/4885WDR77 1989/4885EGFR 2196/4885 |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | RB1, TP53, BRD4 | PRMT5 265/4885WDR77 529/4885EGFR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.